AIM: Although prostate-specific antigen (PSA) screening reduces mortality from prostate cancer, substantial over-diagnosis and subsequent overtreatment are concerns.
Early screening of men for PSA may serve to stratify the male population by risk of future clinical prostate cancer.
METHODS AND MATERIAL: Case-control study nested within the Danish 'Diet, Cancer and Health' cohort of 27,179 men aged 50-64 at enrolment. PSA measured in serum collected at cohort entry in 1993-1997 was used to evaluate prostate cancer risk diagnosed up to 14years after. We identified 911 prostate cancer cases in the Danish Cancer Registry through 31st December 2007 1:1 age-matched with cancer-free controls. Aggressive cancer was defined as ⩾T3 or Gleason score ⩾7 or N1 or M1. Statistical analyses were based on conditional logistic regression with age as underlying time axis.
RESULTS: Total PSA and free-to-total PSA ratio at baseline were strongly associated with prostate cancer risk up to 14years later. PSA was grouped in quintiles and free-to-total PSA ratio divided in three risk groups. The incidence rate ratio for prostate cancer was 150 (95% confidence interval, 72-310) among men with a total PSA in the highest quintile (>5.1ng/ml) compared to the lowest (< 0.80ng/ml). The risk of aggressive cancer was highly elevated in men with a PSA level in the highest quintile. The results indicate that one-time measurement of PSA could be used in an individualised screening strategy, sparing a large proportion of men from further PSA-based screening.
Written by:
Larsen SB, Brasso K, Iversen P, Christensen J, Christiansen M, Carlsson S, Lilja H, Friis S, Tjønneland A, Dalton SO. Are you the author?
Danish Cancer Society Research Center, Strandboulevarden 49, 2100 Copenhagen Ø, Denmark.
Reference: Eur J Cancer. 2013 May 16. pii: S0959-8049(13)00327-4.
doi: 10.1016/j.ejca.2013.04.015
PubMed Abstract
PMID: 23684783
UroToday.com Prostate Cancer Section
